I walked into a pharmacy. The security guard handed me a priority number. He didn’t ask which type I wanted: ...

In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the ...